Drug Profile

Tavapadon - Cerevel Therapeutics

Alternative Names: CVL 751; PF 6649751; PF-06649751

Latest Information Update: 21 Apr 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Pfizer
Developer Cerevel Therapeutics; Pfizer
Class Antiparkinsonians; Small molecules
Mechanism of Action Dopamine D1 receptor agonists; Dopamine D5 receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase III Parkinson's disease

Most Recent Events

26 Mar 2025 AbbVie initiates enrollment in its phase I relative bioavailability trial (In volunteers) in USA (PO, Tablet) (NCT06895356)
26 Mar 2025 AbbVie plans a phase I relative bioavailability trial in Healthy volunteers (PO, Tablet) , (NCT06895356)
09 Dec 2024 AbbVie announces intention to submit a NDA to the US FDA for Parkinson's disease in 2025

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com